Canagliflozin Reduces the Risk of Kidney Failure in Patients with Type 2 Diabetes Mellitus and Nephropathy: The CREDENCE Randomized Trial

J Gen Intern Med. 2021 Feb 5. doi: 10.1007/s11606-020-06216-z. Online ahead of print.
No abstract available